BTIG raised the firm’s price target on Stryker to $383 from $374 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results in MedTech. The sector had “solid returns” as Providers outperformed among healthcare sub-sectors at 10.5% for iShares U.S. Healthcare Providers ETF (IHF), and these results track largely in line with fundamental feedback during Q3 as procedure volumes have been healthy and demand is strong, the analyst tells investors in a research note. Channel checks in many sub-sectors also point to sustained procedure demand continuing into 2025 as demographics and low unemployment provide support, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target raised to $380 from $365 at Evercore ISI
- Stryker completes acquisition of Vertos Medical
- Wolfe starts Zimmer Biomet at Peer Perform, sees $115-$130 fair value
- Wolfe starts Stryker with an Outperform on leading orthopedics portfolio
- Stryker initiated with an Outperform at Wolfe Research